B + L debuts Incise IOL in Europe

June 10, 2013

Incise with enhanced acrylic and improved Stellaris system capabilities was designed to minimize posterior capsular opacification.

Aliso Viejo, CA, and Kingston, UK-Bausch + Lomb has launched Incise microincision intraocular lens (IOL). This acrylic IOL, combined with the Stellaris Vision Enhancement System, enables surgeons to perform microincision cataract surgery less than 2mm, delivering less invasive surgery for a more rapid visual recovery.

The Incise IOL’s aspheric optics were designed to enhance visual quality, according to the company. The combination of enhanced acrylic, improved Stellaris system capabilities, with a single use Incise Viscoject Bioinjector enables 1.8mm in-the-bag and 1.4mm wound assist implantation that enables surgeons to benefit from a controlled sub-2mm MICS procedure.

Incise was designed to minimize posterior capsular opacification (PCO), a common long-term problem with IOLs that can cause patient vision to become clouded post-surgery. INCISE has a 360 degree barrier edge with a radius of curvature of 5 micro-m.

Although the Incise lens received CE Mark approval in the European Union, it is not approved for sale in the U.S.

The analyses report a higher rate of drusen and small retinal hemorrhages detected by the Optomap image-assisted technique, identifying between 90%-100% compared with the traditional method that identified only 15%-62% of these lesions.

"This study confirms what our clinical experience tells us-the use of digital technology can help us to improve the examination and care we give our patients," said Kristen Brown, OD, FAAO, the principal study investigator.

Related Content:

News